Isoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller, Letícia Nogueira, Theresa P. Devasia et al. · CA A Cancer Journal for Clinicians · 2022 · 3.7K citations · Full text

Medicine, Oncology, Population Health Sciences +17

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2020 · 650 citations

Pharmacy, Oncology, Pharmacotherapy +15

Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma

Chiara Vardabasso, Alexandre Gaspar‐Maia, Dan Hasson et al. · Molecular Cell · 2015 · 214 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

E2F1 in Melanoma Progression and Metastasis

Vijay Alla, David Engelmann, Annett Niemetz et al. · JNCI Journal of the National Cancer Institute · 2009 · 139 citations

Medicine, Molecular Biology, Oncology +17